Janus Henderson Group PLC Has $12.54 Million Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Janus Henderson Group PLC cut its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 28.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,252,240 shares of the company's stock after selling 884,847 shares during the period. Janus Henderson Group PLC owned approximately 4.87% of 4D Molecular Therapeutics worth $12,544,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. KLP Kapitalforvaltning AS bought a new stake in 4D Molecular Therapeutics in the 4th quarter valued at $48,000. PNC Financial Services Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock valued at $51,000 after purchasing an additional 3,630 shares during the period. Daiwa Securities Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 5,291.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock valued at $55,000 after purchasing an additional 9,737 shares in the last quarter. Virtus ETF Advisers LLC boosted its position in shares of 4D Molecular Therapeutics by 173.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,333 shares of the company's stock worth $58,000 after buying an additional 6,560 shares during the period. Finally, Fox Run Management L.L.C. acquired a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth about $69,000. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Price Performance

FDMT stock traded down $0.01 during midday trading on Thursday, reaching $3.54. The company had a trading volume of 141,649 shares, compared to its average volume of 832,967. 4D Molecular Therapeutics, Inc. has a 1-year low of $2.24 and a 1-year high of $28.93. The stock has a 50 day moving average price of $3.27 and a 200-day moving average price of $5.03. The company has a market capitalization of $164.13 million, a price-to-earnings ratio of -1.24 and a beta of 2.87.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). As a group, research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Analyst Ratings Changes

FDMT has been the topic of a number of research reports. Royal Bank of Canada cut their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. The Goldman Sachs Group decreased their target price on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Barclays cut their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. HC Wainwright restated a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Finally, Chardan Capital decreased their price objective on 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, 4D Molecular Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $29.56.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.